Editas Looks To Upregulate Its Fortunes With In Vivo Editing
After ditching its clinical-stage ex vivo candidate in December, the CRISPR-based company is starting all over again with a focus on in vivo therapies and upregulating beneficial genes.
After ditching its clinical-stage ex vivo candidate in December, the CRISPR-based company is starting all over again with a focus on in vivo therapies and upregulating beneficial genes.